Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Encephalitis ll: Pathophysiology01:26

Encephalitis ll: Pathophysiology

Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The association between COVID-19 vaccines and bullous pemphigoid risk: A UK population-based study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Ex vivo Sézary syndrome patient tumor cells are sensitive to ATR inhibition.

The Journal of investigative dermatology·2026
Same author

Overcoming barriers and embedding processes to sustainably deliver high-dose post-stroke aphasia rehabilitation: a mixed methods longitudinal process evaluation.

BMC health services research·2026
Same author

The association between prescribed hormonal contraception and multiple sclerosis risk: a systematic review and meta-analysis.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same author

Genetic Determinants of Multiple Sclerosis Susceptibility in People From Diverse Ancestral Backgrounds.

Neurology·2026
Same author

Therapeutic challenges in patients with multiple sclerosis and ankylosing spondylitis: A case series.

Multiple sclerosis and related disorders·2025
Same journal

Ursodeoxycholic acid inhibits platelet activation and thrombosis via TREM2: Evidence from mouse models and human studies.

British journal of pharmacology·2026
Same journal

Peripheral κ opioid receptor in pain and inflammation: From molecular signalling and gene expression to drug discovery.

British journal of pharmacology·2026
Same journal

Targeting KRAS for cancer therapy.

British journal of pharmacology·2026
Same journal

Fangchinoline alleviates hypertensive heart failure via PGC-1α/STAT6/PPARγ activation of mitophagy against ferroptosis.

British journal of pharmacology·2026
Same journal

The selective degradation of PDE4B shortform, using a PROTAC, leads to inhibition of several hallmarks of cancer in HCT116 cells.

British journal of pharmacology·2026
Same journal

Immune checkpoint inhibitor-induced arrhythmias: Mechanistic insights from clinical and preclinical studies.

British journal of pharmacology·2026
See all related articles

Related Experiment Video

Updated: Jun 4, 2026

Myelin Oligodendrocyte Glycoprotein (MOG35-55) Induced Experimental Autoimmune Encephalomyelitis (EAE) in C57BL/6 Mice
08:03

Myelin Oligodendrocyte Glycoprotein (MOG35-55) Induced Experimental Autoimmune Encephalomyelitis (EAE) in C57BL/6 Mice

Published on: April 15, 2014

Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS).

Cris S Constantinescu1, Nasr Farooqi, Kate O'Brien

  • 1Division of Clinical Neurology, School of Clinical Sciences, University of Nottingham, Queen's Medical Centre, Nottingham, UK. cris.constantinescu@nottingham.ac.uk

British Journal of Pharmacology
|March 5, 2011
PubMed
Summary
This summary is machine-generated.

Experimental autoimmune encephalomyelitis (EAE) models multiple sclerosis (MS) by mimicking its key features like inflammation and demyelination. This versatile EAE model aids in understanding neuroinflammation and developing therapies for MS and other autoimmune conditions.

More Related Videos

Induction of Experimental Autoimmune Encephalomyelitis in Mice and Evaluation of the Disease-dependent Distribution of Immune Cells in Various Tissues
08:47

Induction of Experimental Autoimmune Encephalomyelitis in Mice and Evaluation of the Disease-dependent Distribution of Immune Cells in Various Tissues

Published on: May 8, 2016

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Related Experiment Videos

Last Updated: Jun 4, 2026

Myelin Oligodendrocyte Glycoprotein (MOG35-55) Induced Experimental Autoimmune Encephalomyelitis (EAE) in C57BL/6 Mice
08:03

Myelin Oligodendrocyte Glycoprotein (MOG35-55) Induced Experimental Autoimmune Encephalomyelitis (EAE) in C57BL/6 Mice

Published on: April 15, 2014

Induction of Experimental Autoimmune Encephalomyelitis in Mice and Evaluation of the Disease-dependent Distribution of Immune Cells in Various Tissues
08:47

Induction of Experimental Autoimmune Encephalomyelitis in Mice and Evaluation of the Disease-dependent Distribution of Immune Cells in Various Tissues

Published on: May 8, 2016

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Area of Science:

  • Neuroimmunology
  • Experimental Neurology
  • Autoimmune Disease Research

Background:

  • Experimental autoimmune encephalomyelitis (EAE) is a widely used animal model for studying multiple sclerosis (MS).
  • EAE recapitulates critical pathological hallmarks of MS, including inflammation, demyelination, axonal damage, and glial cell activation.
  • The model also encompasses resolution of inflammation and remyelination processes, making it valuable for comprehensive MS research.

Purpose of the Study:

  • To review the utility and complexities of EAE as a model for multiple sclerosis (MS).
  • To highlight EAE's role in understanding neuroinflammation, demyelination, and autoimmune mechanisms.
  • To discuss EAE's application in the preclinical testing and development of therapeutic interventions for MS.

Main Methods:

  • Review of existing literature on EAE induction, pathology, and immunological aspects.
  • Analysis of EAE's relevance to multiple sclerosis (MS) pathogenesis and therapeutic strategies.
  • Examination of the heterogeneity in EAE models and its implications for translational research.

Main Results:

  • EAE serves as a robust model for key MS pathologies, including inflammation and demyelination.
  • The model exhibits complex neuropharmacology, crucial for testing MS therapeutics.
  • Heterogeneity in EAE susceptibility and response underscores its versatility but also challenges direct translation to human MS.

Conclusions:

  • EAE is a highly adaptable model for exploring immune-mediated neuroinflammation and demyelination in MS.
  • Its variability necessitates careful tailoring to specific research questions but offers opportunities to study protective mechanisms.
  • EAE remains indispensable for the preclinical development and validation of novel therapeutic interventions for MS and related autoimmune neurological disorders.